Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients.

Kostianovsky A, Charles P, Alves JF, Goulet M, Pagnoux C, Le Guern V, Mouthon L, Krivine A, Villiger P, Launay O, Guillevin L; French Vasculitis Study Group.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S83-9. Epub 2012 May 11.

PMID:
22640652
2.

High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.

Campos LM, Silva CA, Aikawa NE, Jesus AA, Moraes JC, Miraglia J, Ishida MA, Bueno C, Pereira RM, Bonfa E.

Arthritis Care Res (Hoboken). 2013 Jul;65(7):1121-7. doi: 10.1002/acr.21948.

3.

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.

Zuccotti GV, Pariani E, Scaramuzza A, Santoro L, Giani E, Macedoni M, Gazzarri A, Anselmi G, Amendola A, Zanetti A.

Diabet Med. 2011 Dec;28(12):1530-6. doi: 10.1111/j.1464-5491.2011.03449.x.

PMID:
21916971
4.

Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.

Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Boršo D, Frimmel S, Riebold D, Reisinger EC.

Vaccine. 2011 Feb 1;29(6):1228-34. doi: 10.1016/j.vaccine.2010.11.092. Epub 2010 Dec 15.

PMID:
21167116
5.

Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients.

Aikawa NE, Trudes G, Campos LM, Pereira RM, Moraes JC, Ribeiro AC, Miraglia J, Timenetsky Mdo C, Bonfa E, Silva C.

Lupus. 2013 Nov;22(13):1394-8. doi: 10.1177/0961203313505926. Epub 2013 Sep 27.

PMID:
24076765
6.

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.

Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.

Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29.

PMID:
21803100
7.

Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.

Carraro G, Naso A, Montomoli E, Gasparini R, Camerini R, Panatto D, Tineo MC, De Giorgi L, Piccirella S, Khadang B, Ceracchi M, De Rosa A.

Vaccine. 2012 Feb 1;30(6):1170-80. doi: 10.1016/j.vaccine.2011.12.014. Epub 2011 Dec 14.

PMID:
22178096
8.

Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.

Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DB, Wechsler B, Hervier B, Miyara M, Morel N, Le Corre N, Arnaud L, Piette JC, Musset L, Autran B, Rozenberg F, Amoura Z.

Arthritis Rheum. 2011 Nov;63(11):3502-11. doi: 10.1002/art.30576.

9.

Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.

Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, Tchidjou HK, Aquilani A, Cotugno N, Alghisi F, Lucidi V, Rossi P, Douagi I.

Biologicals. 2012 Mar;40(2):134-9. doi: 10.1016/j.biologicals.2011.12.001. Epub 2012 Jan 20.

PMID:
22261282
10.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.

Vaccine. 2012 May 14;30(23):3470-7. doi: 10.1016/j.vaccine.2012.03.017. Epub 2012 Mar 22.

PMID:
22446638
11.

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N.

Vaccine. 2012 Aug 3;30(36):5407-16. doi: 10.1016/j.vaccine.2012.06.009. Epub 2012 Jun 17.

12.

[Flu vaccine and auto-immune and/or inflammatory diseases].

Duchet-Niedziolka P, Hanslik T, Mouthon L, Guillevin L, Launay O.

Presse Med. 2011 Mar;40(3):248-52. doi: 10.1016/j.lpm.2010.12.003. Epub 2011 Jan 12. French.

PMID:
21232908
13.

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.

Cullen G, Bader C, Korzenik JR, Sands BE.

Gut. 2012 Mar;61(3):385-91. doi: 10.1136/gutjnl-2011-300256. Epub 2011 Jul 13.

PMID:
21757451
14.

Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases.

Saad CG, Borba EF, Aikawa NE, Silva CA, Pereira RM, Calich AL, Moraes JC, Ribeiro AC, Viana VS, Pasoto SG, Carvalho JF, França IL, Guedes LK, Shinjo SK, Sampaio-Barros PD, Caleiro MT, Goncalves CR, Fuller R, Levy-Neto M, Timenetsky Mdo C, Precioso AR, Bonfa E.

Ann Rheum Dis. 2011 Jun;70(6):1068-73. doi: 10.1136/ard.2011.150250.

PMID:
21540203
15.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
16.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.

PMID:
21816199
17.

Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.

Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, Chotpitayasunondh C.

Vaccine. 2012 Feb 1;30(6):1108-14. doi: 10.1016/j.vaccine.2011.12.023. Epub 2011 Dec 15.

PMID:
22178515
18.

Diminished immunogenicity to pandemic H1N1 2009 influenza vaccine in subjects with severe motor and intellectual disability.

Hara M, Hanaoka T, Mizushima T, Honma J, Maeda K, Ohfuji S, Tanaka K, Hirota Y.

Vaccine. 2011 Oct 26;29(46):8323-9. doi: 10.1016/j.vaccine.2011.08.097. Epub 2011 Sep 3.

PMID:
21893146
19.
20.

Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant.

Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, Fortuno ES 3rd, Xu W, Shi L, Kukreti V, Crump M, Kuruvilla J.

Leuk Lymphoma. 2013 Jul;54(7):1387-95. doi: 10.3109/10428194.2012.742524. Epub 2013 Jan 8.

PMID:
23240909
Items per page

Supplemental Content

Write to the Help Desk